乳腺癌患者的药学门诊管理专家共识

2021-07-16 广东省药学会 今日药学.

广东省药学会于2017及2018年分别推动药学门诊与外科药学工作,2018年发布了《药学门诊试行标准》,2021年出版了学界第一本《外科药学》教材,这两项工作是全程化药学服务的两个重要组成部分。乳腺癌

中文标题:

乳腺癌患者的药学门诊管理专家共识

发布机构:

广东省药学会

发布日期:

2021-07-16

简要介绍:

广东省药学会于2017及2018年分别推动药学门诊与外科药学工作,2018年发布了《药学门诊试行标准》,2021年出版了学界第一本《外科药学》教材,这两项工作是全程化药学服务的两个重要组成部分。乳腺癌是女性最常见的肿瘤,占我国所有女性癌的15%,并且发病率呈逐年上升的趋势。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=乳腺癌患者的药学门诊管理专家共识_广东省药学会.pdf)] GetToolGuiderByIdResponse(projectId=1, id=27b5a1c0021a00d2, title=乳腺癌患者的药学门诊管理专家共识, enTitle=, guiderFrom=今日药学., authorId=0, author=, summary=广东省药学会于2017及2018年分别推动药学门诊与外科药学工作,2018年发布了《药学门诊试行标准》,2021年出版了学界第一本《外科药学》教材,这两项工作是全程化药学服务的两个重要组成部分。乳腺癌, cover=https://img.medsci.cn/2021729/1627488887202_2020535.jpg, journalId=0, articlesId=null, associationId=1082, associationName=广东省药学会, associationIntro=广东省药学会前身为1945年成立的广州药师公会,1951年成为中国药学会广州分会。1958年在原有基础上扩大组织,成立中国药学会广东分会,负责组织全省药学科技工作者的相关活动。1985年起,中国药学会广东分会一直挂靠在广东省食品药品监督管理局(省医药管理局)。1991年,按民政部门文件要求更名为广东省药学会。, copyright=0, guiderPublishedTime=Fri Jul 16 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #666666;">广东省药学会于2017及2018年分别推动药学门诊与外科药学工作,2018年发布了《药学门诊试行标准》,2021年出版了学界第一本《外科药学》教材,这两项工作是全程化药学服务的两个重要组成部分。乳腺癌是女性最常见的肿瘤,占我国所有女性癌的15%,并且发病率呈逐年上升的趋势。&nbsp;</span></p>, tagList=[TagDto(tagId=285, tagName=乳腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=285, guiderKeyword=乳腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=28780, appHits=105, showAppHits=0, pcHits=460, showPcHits=28587, likes=0, shares=10, comments=8, approvalStatus=1, publishedTime=Sat Jul 31 22:52:04 CST 2021, publishedTimeString=2021-07-16, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Thu Jul 29 00:14:57 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 18:18:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=乳腺癌患者的药学门诊管理专家共识_广东省药学会.pdf)])
乳腺癌患者的药学门诊管理专家共识_广东省药学会.pdf
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1062524, encodeId=3bd21062524d2, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 10:12:49 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009381, encodeId=10741009381bd, content=赞比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=744d5577765, createdName=ms6000000987226835, createdTime=Thu Aug 19 10:05:05 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005845, encodeId=d95a10058453c, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Sat Aug 07 17:03:29 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005044, encodeId=7fd41005044fd, content=非常详细,拜读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:08:28 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003567, encodeId=d181100356e6d, content=理学物理诊断, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 29 11:41:13 CST 2021, time=2021-07-29, status=1, ipAttribution=)]
    2021-10-21 ms4000000670558531

    good

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1062524, encodeId=3bd21062524d2, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 10:12:49 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009381, encodeId=10741009381bd, content=赞比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=744d5577765, createdName=ms6000000987226835, createdTime=Thu Aug 19 10:05:05 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005845, encodeId=d95a10058453c, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Sat Aug 07 17:03:29 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005044, encodeId=7fd41005044fd, content=非常详细,拜读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:08:28 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003567, encodeId=d181100356e6d, content=理学物理诊断, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 29 11:41:13 CST 2021, time=2021-07-29, status=1, ipAttribution=)]
    2021-08-19 ms6000000987226835

    赞比

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1062524, encodeId=3bd21062524d2, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 10:12:49 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009381, encodeId=10741009381bd, content=赞比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=744d5577765, createdName=ms6000000987226835, createdTime=Thu Aug 19 10:05:05 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005845, encodeId=d95a10058453c, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Sat Aug 07 17:03:29 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005044, encodeId=7fd41005044fd, content=非常详细,拜读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:08:28 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003567, encodeId=d181100356e6d, content=理学物理诊断, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 29 11:41:13 CST 2021, time=2021-07-29, status=1, ipAttribution=)]
    2021-08-07 ms9000001873897494

    受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1062524, encodeId=3bd21062524d2, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 10:12:49 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009381, encodeId=10741009381bd, content=赞比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=744d5577765, createdName=ms6000000987226835, createdTime=Thu Aug 19 10:05:05 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005845, encodeId=d95a10058453c, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Sat Aug 07 17:03:29 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005044, encodeId=7fd41005044fd, content=非常详细,拜读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:08:28 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003567, encodeId=d181100356e6d, content=理学物理诊断, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 29 11:41:13 CST 2021, time=2021-07-29, status=1, ipAttribution=)]
    2021-08-04 ms9000001873897494

    非常详细,拜读

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1062524, encodeId=3bd21062524d2, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69ff5642636, createdName=ms4000000670558531, createdTime=Thu Oct 21 10:12:49 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009381, encodeId=10741009381bd, content=赞比, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=744d5577765, createdName=ms6000000987226835, createdTime=Thu Aug 19 10:05:05 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005845, encodeId=d95a10058453c, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Sat Aug 07 17:03:29 CST 2021, time=2021-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1005044, encodeId=7fd41005044fd, content=非常详细,拜读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Aug 04 09:08:28 CST 2021, time=2021-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003567, encodeId=d181100356e6d, content=理学物理诊断, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62a85535130, createdName=ms3000001999514966, createdTime=Thu Jul 29 11:41:13 CST 2021, time=2021-07-29, status=1, ipAttribution=)]
    2021-07-29 ms3000001999514966

    理学物理诊断

    0

拓展阅读

乳腺癌HER2检测指南(2009版)

中国肿瘤科相关专家小组(统称) · 2009-12-01

2010 乳腺癌骨转移和骨相关疾病临床诊疗专家共识(2010版)

乳腺癌骨转移和骨相关疾病临床诊疗专家组 · 2010-01-01

2010 SBI/ACR推荐建议:乳腺癌影像学筛查

乳腺影像学会(SBI,Society of Breast Imaging) · 2010-01-20

2010 人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2010-02-01

2010 ASCO-CAP指南:乳腺癌患者雌激素和雄激素受体的免疫组化检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-04-19

2010 ASCO指南:激素受体阳性乳腺癌妇女的辅助内分泌治疗

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2010-07-12